Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fezolinetant - Ogeda

Drug Profile

Fezolinetant - Ogeda

Alternative Names: ESN-364

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Euroscreen
  • Developer Ogeda
  • Class Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Gonadal steroid hormone modulators; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hot flashes
  • Phase II Polycystic ovary syndrome; Uterine leiomyoma
  • Preclinical Weight gain
  • Discontinued Benign prostatic hyperplasia; Endometriosis

Most Recent Events

  • 06 Aug 2019 Phase-III clinical trials in Hot flashes in Canada, Europe, USA (PO)
  • 10 Jul 2019 Astellas Pharma initiates enrolment in the phase III SKYLIGHT 2 trial in Hot flashes in USA (NCT04003142)
  • 01 Jul 2019 Astellas Pharma plans the phase III SKYLIGHT 4™ trial for Hot flashes in USA, Canada and Europe (PO) (NCT04003389)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top